Literature DB >> 31551628

Prevalence of chronic respiratory disease in urban and rural Uganda.

Trishul Siddharthan1, Matthew Grigsby1, Brooks Morgan1, Robert Kalyesubula2, Robert A Wise1, Bruce Kirenga2, William Checkley1.   

Abstract

OBJECTIVE: To determine the prevalence of chronic respiratory diseases in urban and rural Uganda and to identify risk factors for these diseases.
METHODS: The population-based, cross-sectional study included adults aged 35 years or older. All participants were evaluated by spirometry according to standard guidelines and completed questionnaires on respiratory symptoms, functional status and demographic characteristics. The presence of four chronic respiratory conditions was monitored: chronic obstructive pulmonary disease (COPD), asthma, chronic bronchitis and a restrictive spirometry pattern.
FINDINGS: In total, 1502 participants (average age: 46.9 years) had acceptable, reproducible spirometry results: 837 (56%) in rural Nakaseke and 665 (44%) in urban Kampala. Overall, 46.5% (698/1502) were male. The age-adjusted prevalence of any chronic respiratory condition was 20.2%. The age-adjusted prevalence of COPD was significantly greater in rural than urban participants (6.1 versus 1.5%, respectively; P < 0.001), whereas asthma was significantly more prevalent in urban participants: 9.7% versus 4.4% in rural participants (P < 0.001). The age-adjusted prevalence of chronic bronchitis was similar in rural and urban participants (3.5 versus 2.2%, respectively; P = 0.62), as was that of a restrictive spirometry pattern (10.9 versus 9.4%; P = 0.82). For COPD, the population attributable risk was 51.5% for rural residence, 19.5% for tobacco smoking, 16.0% for a body mass index < 18.5 kg/m2 and 13.0% for a history of treatment for pulmonary tuberculosis.
CONCLUSION: The prevalence of chronic respiratory disease was high in both rural and urban Uganda. Place of residence was the most important risk factor for COPD and asthma.

Entities:  

Mesh:

Year:  2019        PMID: 31551628      PMCID: PMC6747035          DOI: 10.2471/BLT.18.216523

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


Introduction

Chronic respiratory disease affects one billion people worldwide and is a leading cause of death. Most forms of the disease are noncommunicable, such as chronic obstructive pulmonary disease (COPD), asthma, chronic bronchitis, occupational lung disease and pulmonary hypertension. Currently, the associated morbidity and mortality principally occur in low- and middle-income countries, where the disease burden is expected to rise as rapid economic gains lead to increases in longevity, industrialization and tobacco consumption.– In addition to its impact on individuals, this epidemiological transition has substantial direct and indirect economic implications. Urbanization has been associated with noncommunicable diseases, including chronic respiratory disease,, and is expected to increase as virtually all future population growth will be concentrated in urban areas. There are particular concerns about sub-Saharan Africa, where rapid urbanization and population growth are coupled with an inadequate health infrastructure and poor urban planning. Little is known about the association between urbanization and the shifting burden of chronic respiratory disease in low- and middle-income countries, particularly those in sub-Saharan Africa. Previous studies have examined the prevalence of COPD in either rural or urban settings,– but none has investigated how the pattern of chronic respiratory disease varies across different residential settings, with the aim of evaluating the impact of the urban environment. Moreover, understanding of the population attributable risk (PAR) for different chronic respiratory diseases in African populations is limited. Nevertheless, COPD has been closely linked to household air pollution in rural areas in low- and middle-income countries and the disease burden is expected to increase in urban areas with the growing prevalence of tobacco smoking. The primary aim of this study was to examine variations in the prevalence of different chronic respiratory diseases and their attributable risk factors between urban and rural Uganda. In both settings, we assessed the respiratory symptoms and functional status of individuals with obstructive lung disease.

Methods

We conducted a cross-sectional, population-based cohort study in an urban centre and a rural district in Uganda. The urban sample was drawn from Kampala, the capital city, which had a population of 1.5 million in an estimated 416 070 households in 2014. The rural sample was drawn from Nakaseke, a health district covering 43 167 households with an estimated population of 208 500., Nakaseke, which is located 50 km from downtown Kampala and 14 km from the nearest highway, has been defined as rural by the Uganda Bureau of Statistics (Fig. 1).
Fig. 1

Kampala (urban) and Nakaseke (rural) enumeration areas, study of chronic respiratory disease, Uganda, 2015–2016

Kampala (urban) and Nakaseke (rural) enumeration areas, study of chronic respiratory disease, Uganda, 2015–2016 Note: In each image, the highlighted area represents one of the 25 enumeration areas selected randomly in each setting with the probability of selection proportional to the population size of the enumeration area. Maps obtained from Google Earth version 9.0 (2017 Apr 8). Kampala, Uganda: 0°20’51”N, 32° 35’15”E, Eye alt 1,176m. CNES/Airbus 2018. Nakaseke, Uganda: 0°41’59”N, 32° 24’42”E, Eye alt 1,176m. DigitalGlobe 2018. Twenty-five enumeration areas each were selected for the urban and rural setting, with the probability of selection proportional to the population size of the enumeration area, and 1000 adults were randomly sampled in each setting. Fieldworkers conducted home visits between November 2015 and June 2016 to assess eligibility and obtain informed consent. Inclusion criteria included: (i) age 35 years or older; (ii) full-time residency in either Kampala or Nakaseke; and (iii) capacity to consent to the study. Exclusion criteria included having active pulmonary tuberculosis or a current respiratory infection and pregnancy. The study was approved by the institutional review boards of Mulago Hospital and the Uganda National Council of Science and Technology in Kampala, Uganda and the Johns Hopkins School of Medicine in Baltimore, United States of America. Anthropometric measurements were taken in triplicate. Spirometry was carried out using an Easy on-PC spirometer (ndd, Zürich, Switzerland) and participants with low-quality results were asked to repeat the test on another day for up to three attempts. Those with evidence of pulmonary obstruction were tested again after administration of a bronchodilator (i.e. 400 µg of inhaled salbutamol). As there were no established reference parameters for lung function among Ugandans, we used the reference for African American individuals in the United States’ National Health and Nutrition Examination Survey. We defined pulmonary obstruction as a pre-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) below the lower limit of normal (i.e. a z-score ≤ −1.64). We investigated four chronic respiratory conditions: (i) COPD, defined as a post-bronchodilator FEV1/FVC ratio z-score ≤ −1.64; (ii) a restrictive spirometry pattern, defined as a pre-bronchodilator FVC z-score ≤ −1.64 with a post-bronchodilator FEV1/FVC ratio z-score > −1.64; (iii) asthma, defined as a self-reported wheeze, use of asthma medication in the previous 12 months or a physician’s diagnosis of asthma; and (iv) chronic bronchitis, defined as self-reported phlegm production for at least 3 months each year in two successive years. In addition, we examined airflow-limitation reversibility, defined as a post-bronchodilator increase in FEV1 of 12% or more from baseline or an increase in FVC of 200 mL or more. Respiratory symptoms and functional status were evaluated using the St. George’s Respiratory Questionnaire, version 1 of the 36-item short-form health survey (SF-36) and a modified BOLD (Burden of Obstructive Lung Disease) questionnaire,,, all adapted to the local language (i.e. Luganda). Demographic questionnaires asked for details of biomass fuel smoke exposure, human immunodeficiency virus (HIV) infection and history of treatment for pulmonary tuberculosis. Individuals in households that used wood or charcoal for cooking or heating were regarded as being exposed to biomass fuel smoke. Daily smoking was defined as self-reported smoking of one or more cigarettes per day, underweight, as a body mass index (BMI) < 18.5 kg/m2 and obesity, as a BMI ≥ 30 kg/m2.

Biostatistical methods

Our primary aims were to determine how the age- and sex-adjusted prevalence of chronic respiratory diseases varied according to place of residence (i.e. urban or rural) and to estimate the fraction of chronic respiratory disease that could be attributed to urbanization. Risk factors for chronic respiratory conditions were identified using single variable and multivariable logistic regression models; as risk factors, we included sex, age, place of residence, daily smoking, use of biomass fuels, history of treatment for pulmonary tuberculosis, history of HIV infection and BMI. The adjusted odds ratios from these models were used to calculate attributable fractions for different risk factors in our study population and represent the proportional reduction in morbidity that would result if exposure to a particular risk factor were removed. Associations between these risk factors, FEV1, FVC and FEV1/FVC ratio z-scores were evaluated using multivariable linear regression models. In addition, multivariable logistic regression was used to analyse the association between reversibility and these risk factors. For other analyses, a χ or Fisher’s exact test was used to compare proportions between groups and a t test, analysis of variance or Wilcoxon rank–sum test was used to compare continuous variables between subgroups, as appropriate. All analyses were carried out in R (The R Foundation, Vienna, Austria) and we used the epitools package to perform direct standardization by age using population structure data for 2015 from the Uganda Bureau of Statistics.,,

Results

Of the 2000 individuals originally identified for enrolment in the study, 1772 met inclusion criteria, consented and agreed to undergo spirometry. Ultimately, 84.8% (1502/1772) had acceptable and reproducible spirometry results (Table 1): their average age was 46.9 years (standard deviation, SD: 10.6) and 46.5% (689/1502) were male. Self-reported biomass fuel smoke exposure was high in both rural and urban settings; in rural settings, 99.6% (832/837) of individuals reported using biomass fuels for cooking. The type of biomass fuel varied: 92.3% (771/837) of rural participants reported using wood, whereas 86.0% (564/665) of urban participants reported using charcoal. We did not find any difference between the settings in self-reported history of HIV infection or treatment for pulmonary tuberculosis or in household size. However, a significantly greater percentage of participants in the urban setting had a secondary education (P < 0.001).
Table 1

Study participants, chronic respiratory disease in rural and urban Uganda, 2015–2016

CharacteristicRural sample (n = 837)Urban sample (n = 665)P
Age in years, mean (SD)49.1 (11.2)44.1 (8.9)< 0.001
Male sex, no. (%)380 (45.4)318 (47.8)0.40
Height in m, mean (SD)1.60 (0.1)1.62 (0.1)< 0.001
BMI, mean (SD)24.0 (4.5)25.9 (5.4)< 0.001
Secondary education, no. (%)173 (21)328 (50)< 0.001
Household size, median (IQR)5 (3–7)5 (3–7)0.50
Biomass fuel smoke exposure, no. (%)
Daily biomass fuel use832 (99.6)614 (93.6)< 0.001
Fuel type
    Wood771 (92.3)50 (7.6)< 0.001
    Charcoal61 (7.3)564 (86.0)< 0.001
    Kerosene1 (0.1)22 (3.4)< 0.001
    Propane0 (0.0)12 (1.8)< 0.001
    Electricity2 (0.2)6 (0.9)0.16
    Other0 (0.0)2 (0.3)0.38
Daily tobacco smoking, no. (%)66 (7.9)65 (9.8)0.20
Clinical history, no. (%)
Personal history of treatment for pulmonary tuberculosis22 (3.0)22 (3.6)0.70
Personal history of hypertension80 (9.8)77 (13.3)0.05
Personal history of diabetes5 (0.7)22 (4.5)< 0.001
Personal history of HIV infection68 (8.1)65 (9.8)0.67
Family history of asthma or COPD6 (1.0)137 (33.6)< 0.001

BMI: body mass index; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; IQR: interquartile range; SD: standard deviation.

BMI: body mass index; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; IQR: interquartile range; SD: standard deviation.

Prevalence and risk factors

The overall age- and sex-adjusted prevalence of the four chronic respiratory conditions studied was 20.2%: 20.8% in the rural and 19.4% in the urban setting (P = 0.54). For COPD, the adjusted prevalence was 6.1% in rural participants versus 1.5% in urban participants (P < 0.001). In contrast, asthma was more prevalent in urban participants, in whom the adjusted prevalence was 9.7% compared with 4.4% in rural participants (P < 0.001; Fig. 2). The adjusted prevalence of chronic bronchitis was similar in rural and urban participants (3.5% versus 2.2%, respectively; P = 0.62), as was that of a restrictive spirometry pattern (10.9% versus 9.4%, respectively; P = 0.82).
Fig. 2

Crude and age- and sex-adjusted prevalence of chronic respiratory disease in rural and urban Uganda, 2015–2016

Crude and age- and sex-adjusted prevalence of chronic respiratory disease in rural and urban Uganda, 2015–2016 CI: confidence interval; COPD: chronic obstructive pulmonary disease. Note: Age- and sex-adjusted values were calculated using mid-year estimates for 2015 from the Uganda Bureau of Statistics. The most important factor associated with COPD was living in a rural environment, followed by daily smoking, a BMI < 18.5 kg/m2 and a history of treatment for pulmonary tuberculosis. Specifically, 51.5% (95% confidence interval, CI: 13.5–75.8) of the prevalence of COPD was attributable to living in a rural environment, 19.5% (95% CI: 3.1–45.2) was attributable to daily smoking, 16.0% (95% CI: 4.3–35.1) was attributable to a BMI < 18.5 kg/m2 and 13.0% (95% CI: 3.5–30.8) was attributable to a history of treatment for pulmonary tuberculosis (Fig. 3). For asthma, urban residence was the principal risk factor, with a PAR of 41.4% (95% CI: 14.2–63.1). The PAR of a history of treatment for pulmonary tuberculosis was 9.5% (95% CI: 0.8–29.8) for chronic bronchitis and 5.4% (95% CI: 0.2–16.4) for a restrictive spirometry pattern.
Fig. 3

Risk factors for chronic respiratory conditions, Uganda, 2015–2016

Risk factors for chronic respiratory conditions, Uganda, 2015–2016 BMI: body mass index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; PAR: population attributable risk. Note: The four chronic respiratory conditions considered were chronic obstructive pulmonary disease (COPD), a restrictive spirometry pattern, asthma and chronic bronchitis.

Symptoms and functional status

Although the reported rate of wheezing in the past 12 months was similar in urban and rural participants, the rate of asthma-related medication use and of a previous diagnosis of asthma were significantly higher in urban participants (Table 2). In addition, the reported number of days of work missed due to respiratory disease and the proportion of participants shortness of breath were both higher in the urban setting. There was no significant difference between the groups in respiratory symptoms, as assessed using the St. George’s Respiratory Questionnaire (Table 3). Participants from the urban setting reported fewer impairments in emotional well-being than those from the rural setting: the mean SF-36 score was 57.2 and 77.3 points, respectively (P = 0.001). There was no difference in physical functioning, social functioning, role limitation because of emotional problems, or overall health between the groups.
Table 2

Chronic respiratory disease symptoms, by rural or urban residence, Uganda, 2015–2016

SymptomRural sample (n = 837)
Urban sample (n = 665)
P
No. (%)No. (%)
Asthma
Self-reported wheezing or whistling in the chest in the past 12 months47 (5.6)39 (5.9)0.99
Self-reported medication use to aid breathing in the past 12 months17 (2.0)51 (7.7)< 0.001
Previous diagnosis of asthma7 (0.8)16 (2.4)0.04
Chronic bronchitis 
Self-reported coughing up sputum for at least 3 months in each of two successive years27 (3.2)16 (2.4)0.41
Functional status
Self-reported experience of missing work due to, or having daily activities impeded by, respiratory problems in the past 12 months7 (0.8)26 (3.9)< 0.001
Self-reported shortness of breath on physical exertion73 (8.7)154 (23.2)< 0.001
Table 3

Disease severity and health-related quality of life, study participants with chronic obstructive pulmonary disease in rural and urban Uganda, 2015–2016

ParameterRural participants with COPDa (n = 53)Urban participants with COPDa (n = 12)P
COPD severity,b no. (%)0.04
Mild20 (37.7)3 (25.0)ND
Moderate23 (43.4)8 (66.7)ND
Severe10 (18.9)0 (0.0)ND
Very severe0 (0.0)1 (8.3)ND
St. George’s Respiratory Questionnaire score,20 mean (95% CI)
Symptoms domain48.3 (40.5–56.1)63.2 (51.6–74.8)0.07
Activity domain37.4 (26.8–48.0)34.1 (17.8–50.5)0.76
Psychosocial impact domain27.4 (19.0–35.9)32.0 (21.4–42.7)0.59
Total34.6 (25.5–43.6)38.1 (27.4–48.7)0.70
MRC dyspnoea scale score, median (IQR)2 (1–2)2 (2–2)0.12

CI: confidence interval; COPD: chronic obstructive pulmonary disease; IQR: interquartile range; MRC: Medical Research Council; ND: not determined.

a Chronic obstructive pulmonary disease (COPD) was defined as a post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) below the lower limit of normal (i.e. z-score ≤ 1.64) of the African American reference population in the United States’ National Health and Nutrition Examination Survey (NHANES).

b COPD severity was defined by the GOLD criteria as mild (i.e. FEV1 ≥ 80% predicted), moderate (i.e. 50% ≤ FEV1 < 80% predicted), severe (i.e. 30% ≤ FEV1 < 50% predicted) and very severe (FEV1 < 30% predicted).

CI: confidence interval; COPD: chronic obstructive pulmonary disease; IQR: interquartile range; MRC: Medical Research Council; ND: not determined. a Chronic obstructive pulmonary disease (COPD) was defined as a post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) below the lower limit of normal (i.e. z-score ≤ 1.64) of the African American reference population in the United States’ National Health and Nutrition Examination Survey (NHANES). b COPD severity was defined by the GOLD criteria as mild (i.e. FEV1 ≥ 80% predicted), moderate (i.e. 50% ≤ FEV1 < 80% predicted), severe (i.e. 30% ≤ FEV1 < 50% predicted) and very severe (FEV1 < 30% predicted).

Lung function

In all participants, the mean ± SD pre-bronchodilator FEV1, FVC and FEV1/FVC ratio was 2.53 ± 0.66 L, 3.18 ± 0.75 L and 0.79 ± 0.08, respectively. Fig. 4 presents the distribution of the pre-bronchodilator FEV1/FVC ratio z-score, stratified by place of residence and sex. Both female and male participants in the rural setting had a lower FEV1/FVC ratio than their urban counterparts. Among participants found to have pulmonary obstruction on pre-bronchodilator spirometry, the proportion with a post-bronchodilator FEV1 less than 50% of predicted was higher in the rural than the urban setting: 18.9% (10/53) versus 8.3% (1/12), respectively. However, the difference was not significant (P = 0.67). Fig. 5 shows the estimated effect of sociodemographic and clinical variables on the pre-bronchodilator FEV1, FVC and FEV1/FVC ratio, as determined by multivariable regression analysis. A history of treatment for pulmonary tuberculosis was associated with a low adjusted pre-bronchodilator FEV1 (p<0.001) FVC (P < 0.001) and FEV1/FVC ratio (P < 0.001); living in a rural environment was associated with a low adjusted pre-bronchodilator FEV1 (P = 0.009) and FEV1/FVC ratio (P < 0.001); and self-reported daily tobacco smoking was associated with a low adjusted pre-bronchodilator FEV1/FVC ratio (P = 0.001). Among participants with obstruction, 26.2% (17/65) exhibited reversibility on post-bronchodilator spirometry – the proportion was 50.0% (6/12) in the urban setting and 20.8% (11/53) in the rural setting (P = 0.065).
Fig. 4

Lung function, by sex and place of residence, Uganda, 2015–2016

Fig. 5

Estimated effect of sociodemographic and clinical variables on lung function, Uganda, 2015–2016

Lung function, by sex and place of residence, Uganda, 2015–2016 FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity. Notes: The figure shows pre-bronchodilator FEV1/FVC ratio z-score distribution. Each bar represents a 0.2 increment in z-score. Bars that include the 5th, 10th, 25th, 50th, 75th, 90th or 95th percentile in each distribution are labelled accordingly. The z-scores were calculated using data for the African American reference population in the United States’ National Health and Nutrition Examination Survey (NHANES). Estimated effect of sociodemographic and clinical variables on lung function, Uganda, 2015–2016 BMI: body mass index; CI: confidence interval; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; HIV: human immunodeficiency virus. Notes: Mean absolute differences in z-scores and corresponding 95% CI were obtained from multivariable regression analysis. A normal BMI was in the range 20–25 kg/m2.

Discussion

Although previous studies in Uganda and sub-Saharan Africa have examined the prevalence of, and risk factors for, single respiratory diseases,– few have examined the effect of urbanization on a range of chronic respiratory diseases and none has assessed the PAR. We found that one in every five adults in our study had a chronic respiratory condition and that place of residence was the single most important PAR factor. Specifically, 40% of people with asthma were attributable to urban residence and 50% of people with COPD were attributable to rural residence (a proxy for daily wood smoke exposure), which was a more important factor than tobacco smoking. Many participants in both urban and rural settings had a low lung volumes – this was associated with a history of treatment for pulmonary tuberculosis and being underweight, both of which are common in low- and middle-income countries. Published data on the prevalence of chronic respiratory diseases in low- and middle-income countries cover a wide range. In the BOLD study, the prevalence of COPD in primarily urban environments ranged from 11.4 to 23.8% and that of a restrictive spirometry pattern ranged from 4.2 to 48.7%., In Uganda, a FRESH AIR study found a COPD prevalence of 16.2% in a rural setting. The prevalence in our study was lower: 6.1% in rural and 1.5% in urban participants. There are several possible reasons for the varying estimates: (i) there may have been differences between the studies in the spirometry criteria used to diagnose COPD; (ii) the proportion of tobacco smokers was higher in the FRESH AIR study, which covered a tobacco-growing region, than in our study (36% versus 9%, respectively) or in other parts of Uganda;, and (iii) the average age of participants was lower in our study than in the BOLD study: 47 versus 56 years, respectively. The difference in estimates is unlikely to have been due to differences in the proportion of participants with acceptable spirometry between our study (84.8%) and either BOLD (93%) or FRESH AIR (97%)., The prevalence of chronic bronchitis in our study was 3.3%, which was similar to that in the BOLD study (i.e. 3.1%) and in a population-based study in South Africa (i.e. 2.3 to 2.8%)., We found no difference between urban and rural settings, possibly because both ambient air pollution exposure in urban Kampala and household air pollution exposure in rural Nakaseke were high. The prevalence of wheezing and of a physician’s diagnosis of asthma were similar in our study and in a population-based study in sub-Saharan Africa. Further, the overall prevalence of asthma was higher in our urban sample than our rural sample, which is consistent with findings in both high- and low-income regions, including sub-Saharan Africa., Urban populations, particularly in low- and middle-income countries, are exposed to several risk factors that predispose to smaller lungs and accelerated lung function decline. Early life events, such as childhood respiratory infection, micronutrient deficiency and both ambient and household air pollution, can influence lung size and function, thereby predisposing individuals to obstructive pulmonary disease in adulthood. High cortisol and inflammatory biomarker levels due to urban stressors have been linked to lung injury. Exposure to indoor and outdoor allergens, pollutants and irritants during the early years of life may tip a child’s immune system’s response from a non-asthma to an asthma phenotype, thereby leading to adult asthma. Diminished early exposure to parasites (exposure results in parasite-induced immunoglobulin-E) may lead to the development of atopic disease. Greater exposure to additives and synthetic foods may influence nutrition, which has been associated with asthma. A higher risk of communicable diseases such as tuberculosis and recurrent pulmonary infection can predispose to chronic respiratory diseases such as COPD, restrictive lung disease, asthma, chronic bronchitis and bronchiectasis.,, Our findings reflect the effect of exposure to these risk factors on airway and parenchymal injury and disease and are consistent with previous data on the distribution of chronic respiratory disease in urban and rural environments in low- and middle-income countries.,, The leading risk factor for several chronic respiratory diseases in both urban and rural settings remains chronic inflammation due to exposure to environmental substances. Although cigarette exposure is low in many African countries, it is expected to rise with growing urbanization over the next two decades, thereby increasing the prevalence of chronic respiratory disease. Today, household air pollution remains the leading cause of COPD., In our study, biomass fuel was commonly used for cooking at both rural and urban sites though the type of fuel was different: the primary fuel was wood at rural sites and charcoal at urban sites. We were unable to assess differences in the relative risk of different types of fuel. However, burning wood emits more particulate matter than burning charcoal or liquefied petroleum gas and there have been reports that respiratory symptoms are more common in individuals in low- and middle-income countries who use wood than in those who use charcoal or liquefied petroleum gas. Our study has several strengths. First, it had a large population-based design and comprehensive spirometry and respiratory data were collected. Second, we used the lower limit of normal for African American individuals in the National Health and Nutrition Examination Survey to identify COPD and a restrictive spirometry pattern, this helped prevent overdiagnosis of obstruction and restriction, particularly in elderly people. Third, by calculating PARs, we were able to gain a better understanding of the risk factors for chronic respiratory diseases. Our study also has some potential shortcomings. First, we were unable to recruit 15.2% (270/1772) of individuals who met inclusion criteria after two follow-up visits; nevertheless, our non-response rate was lower than in many other studies. Second, participants who had incomplete spirometry results were predominantly elderly or had severe respiratory disease, which highlights the difficulty of spirometry in those with reduced pulmonary function. The disease burden may therefore, have been underestimated. Third, urban participants were younger than rural participants, which may have affected the crude disease prevalence; however, we calculated age- and sex-adjusted prevalences to reduce the risk of bias. Fourth, we defined asthma as a self-reported wheeze, use of asthma medications or a physician’s diagnosis. The last two criteria are closely linked to health-care access and utilization, which may be influenced by socioeconomic status. Consequently, the higher rates we observed for these two criteria among urban participants may reflect better access to health care. However, post-bronchodilator reversibility, which indicates greater airway reactivity, was significantly more common in urban residents with obstruction. Fifth, we did not assess individual exposure to air pollution. Better understanding of the association between urbanization and chronic respiratory disease requires longitudinal assessment of individual exposure to air pollution. The increase in urbanization over the next two decades is expected to occur almost exclusively in low- and middle-income countries and, by 2030, half of sub-Saharan Africa’s population will reside in an urban area. However, poor infrastructure and a lack of policy interventions aimed at sustainable urban growth will have severe health implications for many people in low- and middle-income countries worldwide. Future public health interventions will depend on a good understanding of the evolving disease burden. Currently, chronic respiratory disease is associated with chronic inflammation throughout life, whether due to household air pollution, the urban microenvironment (e.g. allergens and outdoor air pollution) or recurrent pulmonary infection. As urban dwellers transition to cleaner fuels for cooking and heating, cigarette exposure and outdoor air pollution will become increasingly important risk factors. In summary, we found a high burden of chronic respiratory disease in both rural and urban Uganda. Place of residence was the single most important risk factor: urban residence was the principal risk factor for asthma and rural residence was the principal risk factor for COPD. As urbanization continues in sub-Saharan Africa, the profile and burden of chronic respiratory disease are likely to change in parallel.
  34 in total

Review 1.  Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program.

Authors:  G T Ferguson; P L Enright; A S Buist; M W Higgins
Journal:  Chest       Date:  2000-04       Impact factor: 9.410

2.  Asthma and IgE levels in rural and urban communities of The Gambia.

Authors:  R C Godfrey
Journal:  Clin Allergy       Date:  1975-06

Review 3.  From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis.

Authors:  C Lienhardt
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

4.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

5.  The occurrence of lung cancer in man.

Authors:  M L LEVIN
Journal:  Acta Unio Int Contra Cancrum       Date:  1953

6.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

7.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

8.  Predictors of chronic bronchitis in South African adults.

Authors:  R I Ehrlich; N White; R Norman; R Laubscher; K Steyn; C Lombard; D Bradshaw
Journal:  Int J Tuberc Lung Dis       Date:  2004-03       Impact factor: 2.373

9.  The burden of non communicable diseases in developing countries.

Authors:  Abdesslam Boutayeb; Saber Boutayeb
Journal:  Int J Equity Health       Date:  2005-01-14

10.  Rethinking the "diseases of affluence" paradigm: global patterns of nutritional risks in relation to economic development.

Authors:  Majid Ezzati; Stephen Vander Hoorn; Carlene M M Lawes; Rachel Leach; W Philip T James; Alan D Lopez; Anthony Rodgers; Christopher J L Murray
Journal:  PLoS Med       Date:  2005-05-03       Impact factor: 11.069

View more
  11 in total

1.  Illness representations of chronic obstructive pulmonary disease (COPD) to inform health education strategies and research design-learning from rural Uganda.

Authors:  Emily M Nagourney; Nicole M Robertson; Natalie Rykiel; Trishul Siddharthan; Patricia Alupo; Marysol Encarnacion; Bruce J Kirenga; Robert Kalyesubula; Shumonta A Quaderi; John R Hurst; William Checkley; Suzanne L Pollard
Journal:  Health Educ Res       Date:  2020-08-01

2.  Chronic Obstructive Pulmonary Disease Prevalence and Associated Factors in a Setting of Well-Controlled HIV, A Cross-Sectional Study.

Authors:  Alex Kayongo; Adaeze C Wosu; Tasmia Naz; Faith Nassali; Robert Kalyesubula; Bruce Kirenga; Robert A Wise; Trishul Siddharthan; William Checkley
Journal:  COPD       Date:  2020-05-28       Impact factor: 2.409

3.  Cohort profile: The Chikwawa lung health cohort; a population-based observational non-communicable respiratory disease study of adults in Malawi.

Authors:  Martin W Njoroge; Sarah Rylance; Rebecca Nightingale; Stephen Gordon; Kevin Mortimer; Peter Burney; Jamie Rylance; Angela Obasi; Louis Niessen; Graham Devereux
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

4.  Incidence and predictors of COPD mortality in Uganda: A 2-year prospective cohort study.

Authors:  Patricia Alupo; Adaeze C Wosu; Abdallah Mahofa; Levicatus Mugenyi; Daniel Semakula; Winceslaus Katagira; Bruce Kirenga
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

5.  Lung function and atherosclerosis: a cross-sectional study of multimorbidity in rural Uganda.

Authors:  Rebecca F Gilbert; Cody Cichowitz; Prossy Bibangambah; June-Ho Kim; Linda C Hemphill; Isabelle T Yang; Ruth N Sentongo; Bernard Kakuhikire; David C Christiani; Alexander C Tsai; Samson Okello; Mark J Siedner; Crystal M North
Journal:  BMC Pulm Med       Date:  2022-01-05       Impact factor: 3.317

6.  Non-communicable respiratory disease in Malawi: a systematic review and meta-analysis.

Authors:  Rebecca Nightingale; Hannah Jary; Jamilah Meghji; Sarah Rylance; Jones Masiye; Hastings Chiumia; Jamie Rylance; Kevin Mortimer; Maia Lesosky
Journal:  Malawi Med J       Date:  2020-06       Impact factor: 0.875

7.  Chronic obstructive pulmonary disease in sub-Saharan Africa.

Authors:  B I Awokola; G A Amusa; C P Jewell; G Okello; M Stobrink; L J Finney; N Mohammed; A Erhart; K J Mortimer
Journal:  Int J Tuberc Lung Dis       Date:  2022-03-01       Impact factor: 3.427

8.  A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Country Settings.

Authors:  Trishul Siddharthan; Adaeze C Wosu; Suzanne L Pollard; Shakir Hossen; Patricia Alupo; Timothy Shade; Robert Kalyesubula; Shumonta Quaderi; Robert A Wise; John R Hurst; Bruce Kirenga; William Checkley
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-11-03

9.  An Emerging Syndemic of Smoking and Cardiopulmonary Diseases in People Living with HIV in Africa.

Authors:  Emmanuel Peprah; Mari Armstrong-Hough; Stephanie H Cook; Barbara Mukasa; Jacquelyn Y Taylor; Huichun Xu; Linda Chang; Joyce Gyamfi; Nessa Ryan; Temitope Ojo; Anya Snyder; Juliet Iwelunmor; Oliver Ezechi; Conrad Iyegbe; Paul O'Reilly; Andre Pascal Kengne
Journal:  Int J Environ Res Public Health       Date:  2021-03-18       Impact factor: 3.390

10.  Chronic obstructive pulmonary disease prevalence and associated factors in an urban HIV clinic in a low income country.

Authors:  Ahmed Ddungu; Fred C Semitala; Barbara Castelnuovo; Christine Sekaggya-Wiltshire; William Worodria; Bruce J Kirenga
Journal:  PLoS One       Date:  2021-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.